Skip to main content

Table1 Clinical characteristics CAF and gastric cancer survival in TCGA cohort

From: Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression

Variates Cases Univariate HR 95% CI (P Value) Multivariate HR 95%CI (P value)
OS DFS OS DFS
Age < 50(ref) 20     
  50 219 0.5409–4.15 (0.437) 0.35–2.25 (0.798) 0.55–4.39 (0.4116) 0.35–2.33 (0.8790)
sex Female(ref) 94     
  male 145 0.68–2.03 (0.562) 0.98–3.87 (0.0557) 0.67–2.03 (0.5917) 1.02–4.05 (0.0440)
Lauren classification Intestinal(ref) 99     
  Diffuse 44 0.61–2.57 (0.538) 0.80–4.18 (0.1686) 0.52–2.35 (0.7959) 0.65–3.76 (0.3134)
  NOS 95 0.93–3.03 (0.088) 1.17–4.86 (0.0163) 0.81–2.80 (0.1966) 1.07–4.73 (0.0329)
Stage I/II(ref) 138     
  III 101 0.95–2.71 (0.0783) 0.58–1.91 (0.866) 1.02–3.00 (0.0420) 0.62–2.06 (0.7085)
CAF Low(ref) 73     
  Medium 81 1.04–4.66 (0.0389) 0.67–3.66 (0.3037) 0.97–4.57 (0.0591) 0.54–3.10 (0.5632)
  High 85 1.09–4.73 (0.0285) 1.04–4.91 (0.0398) 1.04–4.71 (0.0391) 0.87–4.24 (0.1081)
  1. OS overall survival, DFS disease-free survival, 95%CI: 95% confidence interval